Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

States race to use COVID-19 vaccines before they expire

07/30/2021 | 01:01am EDT

Hundreds of thousands of COVID-19 vaccine doses have been saved from the trash after U.S. regulators extended their expiration date for a second time, part of a nationwide effort to salvage expiring shots to battle the nation's summer surge in infections.

The Food and Drug Administration on Wednesday sent a letter to shot maker Johnson & Johnson declaring that the doses remain safe and effective for at least six months when properly stored. The FDA's move gives the shots an extra six weeks as public officials press more Americans to get inoculated.

Similar efforts are happening in multiple states as public health officials try to ensure that soon-to-expire shots are put into arms before they must be discarded.

The surge in infections is largely due to the highly contagious delta variant of the coronavirus, which has spread rapidly, particularly among unvaccinated people. Inoculation rates have climbed only slightly after a steep fall from their April peak.

“It’s a critically important time — we have children headed back to school in just a few weeks’ time,” said Juliann Van Liew, director of the public health department in Wyandotte County, Kansas.

Federal health officials have shipped an additional 8 million doses of the J&J shot to states that have not yet been used, according to the Centers for Disease Control and Prevention's vaccine-tracking website. The company did not share specific expiration dates.

The J&J vaccine is not the only one facing expiration. States also report that many Pfizer and Moderna doses are approaching expiration, which is set at six months from the manufacturing date. In Louisiana, about 100,000 Pfizer doses are set to expire in about a week, for example.

Governors are pleading with the public to get vaccinated, and some are offering cash incentives — $100 payments in New Mexico and New York City, among other places.

Some states have set up marketplaces for shot providers or dedicated staff to redistributing about-to-expire vaccines to places that need them. Such efforts are underway in New Jersey, Washington and Wisconsin.

In Iowa and North Dakota, officials say they send vaccines approaching expiration to locations where they are most likely to be used.

“We have a lot of interest from the public in receiving J&J, so if we find doses that may go unused, we will transfer them to providers in need,” said Molly Howell, North Dakota's immunization director.

Lacy Fehrenbach, deputy director for COVID-19 response for the Washington state Department of Health, said officials want the doses used as efficiently as possible.

“Otherwise, we’re working with our providers to move them around, or, of course, the federal government to get them to other places that need it,” she said.

Dr. Clarence Lam, interim executive medical director of occupational health services at Johns Hopkins University, was encouraged by the extension for the J&J shots.

“We hate to see this supply go to waste, especially when there are areas of the world where this is needed,” Lam said. “But now I think we'll be able to better utilize the supply that's already been distributed here in the U.S.”

The J&J vaccine was eagerly anticipated because it involves just one shot and has easy refrigeration requirements.

But use of the vaccine has been hurt by several rare possible side effects. This month, U.S. health regulators added a warning about links to a potentially dangerous neurological reaction. That followed a break in its use in April after the shot was linked to a rare blood clot disorder. Government health advisers said the overall benefits of the shot still greatly outweigh the risks.

Also in April, a Baltimore vaccine factory was shut down by the FDA due to contamination problems, forcing the company to trash the equivalent of tens of millions of doses being made under contract for Johnson & Johnson.

Pfizer and Moderna have already supplied more than enough doses to vaccinate all eligible Americans. More than 150 million Americans have been fully vaccinated with the companies’ two-dose shots. By comparison, just 13 million, or 9%, have been vaccinated with the J&J shot.

All told, nearly 164 million people have been vaccinated, according to the CDC, or just over 49% of the U.S. population.

Associated Press writers Scott Bauer in Madison, Wisconsin; Melinda Deslatte in Baton Rouge, Louisiana; Roxana Hegeman in Belle Plaine, Kansas; Rachel La Corte in Olympia, Washington; James MacPherson in Bismark, North Dakota; and Matthew Perrone in Washington contributed to this report.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.22% 164.75 Delayed Quote.4.98%
MODERNA, INC. -2.63% 430.05 Delayed Quote.321.80%
PFIZER, INC. -1.33% 43.88 Delayed Quote.21.62%
All news about PFIZER, INC.
04:05pMODERNA : Wall Street ends rollercoaster week sharply lower
03:36pPFIZER : FDA advisory panel rejects widespread Pfizer booster shots
03:33pPFIZER : FDA advisory panel soundly rejects a plan to offer Pfizer booster shots..
03:32pFDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine booster
03:32pU.s. fda advisers may vote on potential narrower recommendation of pfizer cov..
03:23pMODERNA : U.S. administers about 384 mln doses of COVID-19 vaccines - CDC
03:03pModerna Drops Ahead of FDA Committee COVID-19 Booster Decision
02:54pPFIZER : US Reportedly to Buy More Doses of Pfizer-BioNTech COVID-19 Vaccine to ..
02:34pMODERNA : Wall Street slides, ending seesaw week in a risk-off mood
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 80 761 M - -
Net income 2021 18 438 M - -
Net Debt 2021 28 980 M - -
P/E ratio 2021 13,2x
Yield 2021 3,55%
Capitalization 249 B 249 B -
EV / Sales 2021 3,45x
EV / Sales 2022 4,07x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 20
Last Close Price 44,47 $
Average target price 45,02 $
Spread / Average Target 1,24%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.21.62%249 329
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
NOVO NORDISK A/S51.34%233 887
ABBVIE INC.0.87%190 996